



Indexed in: PubMed



an Open Access Journal by MDPI

# **Ophthalmic Pharmacology**

Guest Editor:

### Dr. Si Hyung Lee

Department of Ophthalmology, Soonchunhyang University Hospital Bucheon, Bucheon 170, Republic of Korea

Deadline for manuscript submissions:

6 August 2024

# **Message from the Guest Editor**

Dear Colleagues,

For various ophthalmic diseases, the current treatment mainly involves eyedrops and intraocular/periocular injections. However, recent advances in the development of novel therapeutic agents involves gene therapy utilizing viral vectors, stem cell therapies and miRNAs targeting different signaling pathways, which may be also applicable to ophthalmic pharmacological research. This Special Issue will provide new concepts, regimens and drugs for the treatment of various eye diseases, including retinal disorders, glaucoma and other optic neuropathies, as well as ocular surface disorders. We are looking forward to your valuable contribution to this Special Issue.

Dr. Si Hyung Lee Guest Editor













an Open Access Journal by MDPI

### **Editor-in-Chief**

#### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

# **Message from the Editor-in-Chief**

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

#### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

#### **Contact Us**